Publications by authors named "Ke-Xin Tan"
Article Synopsis
- Two different forms of Mn(II)-bridged Silverton-type polyoxomolybdates were synthesized using hydrothermal methods.
- The resulting compounds, Na(HO)[Mn(UMoO)] and (NH)[KNa(μ-O)(HO)Mn(UMoO)]·4.6HO, displayed unique three-dimensional structures.
- One of the compounds showed high efficiency as a heterogeneous catalyst, achieving up to 99% yield in the condensation cyclization reaction producing various valuable pyrazoles.
Article Synopsis
- Ultrasmall Au(MPA) clusters have promising applications in biocatalysis and bioimaging due to their tunable structures and properties.* -
- A study investigated the effects of high doses (300 and 500 mg/kg) of Au nanoclusters (Au NCs) on hematological, tissue, and neurological parameters, finding no significant toxic effects even at these ultrahigh levels.* -
- The findings suggest good biosafety for Au NCs, with important implications for their clinical use in biomedicine, as they show no major organ damage and are mostly metabolized through the kidneys.*
Article Synopsis
- - A novel Ni(II)-based metal-organic framework was synthesized using specific chemical components, creating a unique 3D structure that is interpenetrating and connected in a certain way.
- - This framework displays both stability and strong catalytic properties, making it effective for producing benzimidazoles and pyrazoles under mild conditions.
- - The catalyst can be easily separated and reused, maintaining its high catalytic activity even after seven cycles of use.
Development of resistance to chemo- and radiotherapy in patients suffering from advanced cervical cancer narrows the therapeutic window for conventional therapies. Previously we reported that a combination of the selective BCL-2 family inhibitors ABT-263 and A-1210477 decreased cell proliferation in C33A, SiHa and CaSki human cervical cancer cell lines. As ABT-263 binds to both BCL-2 and BCL-XL with high affinity, it was unclear whether the synergism of the drug combination was driven either by singly inhibiting BCL-2 or BCL-XL, or inhibition of both.
View Article and Find Full Text PDF